Evidence on the interplay between prescribing decisions and insurance authorization processes is limited.<h4>Objectives</h4>To explore knowledge, attitudes, prescribing practices, and authorization decision-making related to SGLT2 inhibitors for HF among treating physicians and insurance physicians in Jordan, and to identify system-level barriers to evidence-based use.<h4>Methods</h4>An explanatory sequential mixed-methods design was used. This evidence concerns the gene SLC5A2 and hydrops fetalis.